VISCHER has advised TargImmune on the deal.
TargImmune Therapeutics has closed its 2021 financing round, raising CHF 17.7m.
TargImmune is a private Swiss-based biotechnology firm focused on drug development using novel targeted immunotherapies. The principal technology is the CTPIC technology platform that utilizes a proprietary non-viral vector to target and destroy cancer cells that overexpress certain receptors.
The VISCHER team was led by Matthias Staehelin (Picture) with Francesca Pesenti and Nicolai Bleskie (all Corporate/M&A).
Law Firms: VISCHER AG;
Clients: TargImmune Therapeutics;